Peroxisome proliferator-activated receptor ␥ (PPAR␥) is a member of the nuclear receptor superfamily that acts as a key player in adipocyte differentiation, glucose metabolism, and macrophage differentiation. Osteopontin (OPN), a component of extracellular matrix, is elevated during neointimal formation in the vessel wall and is synthesized by macrophages in atherosclerotic plaques. In the present study, we investigated the molecular mechanisms regulating OPN gene expression by PPAR␥ in THP-1 cells, a cell line derived from human monocytic leukemia cells. Northern and Western blot analyses showed that exposure of THP-1 cells to PMA (phorbol 12-myristate 13-acetate) increases OPN mRNA and protein levels in a time-dependent manner. PMA-induced OPN expression was significantly decreased by troglitazone (Tro) and other PPAR␥ ligands. Transient transfection assays of the human OPN promoter/luciferase construct showed that PPAR␥ represses OPN promoter activity, and the PPAR␥-responsive region within the OPN promoter lies between Ϫ1000 and Ϫ970 relative to the transcription start site. Site-specific mutation analysis and electrophoretic mobility shift assays indicated that a homeobox-like A/T-rich sequence between Ϫ990 and Ϫ981, which functions as a binding site for PMA-induced nuclear factors other than PPAR␥, mediates the repression of OPN expression by Tro. Furthermore, concatenated A/T-rich sequences conferred the PPAR␥ responsiveness on the heterologous promoter. Taken together, these data suggest that PPAR␥ ligand inhibits OPN gene expression through the interference with the binding of nuclear factors to A/T-rich sequence in THP-1 cells. (Circ Res. 2002;90:348-355.) 
lecular mechanism of PPAR␥-mediated OPN gene expression remains to be determined.
In the present study, we examined the regulation of OPN gene expression by PPAR␥ ligand in THP-1 cells and defined the molecular mechanisms behind the observation. We determined the cis-regulatory sequence within the OPN gene promoter, which is targeted by PPAR␥. Our results represent one of the molecular mechanisms by which PPAR␥ regulates the extracellular matrix gene implicated in atherosclerotic progression and vascular calcification.
Materials and Methods

Cell Cultures
THP-1, C2/2 (rabbit aorta-derived smooth muscle cells), and COS-7 cells (African monkey kidney cells) were obtained from American Type Culture Collection (ATCC; Manassas, Va). Suspension cell cultures of THP-1 cells were grown to a density of 1ϫ10 6 cells/mL in RPMI 1640 medium supplemented with 10% (vol/vol) fetal bovine serum (FBS). C2/2 cells derived from rabbit-cultured vascular smooth muscle cells were previously described. 19 C2/2 and COS-7 cells were grown at 37°C in a 5% CO 2 atmosphere in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS and 1% penicillin/streptomycin.
Northern Blot Analysis
Total RNA was isolated using the ISOGEN reagent (Nippongene) in accordance with the manufacturer's instruction. Northern blot analysis was performed as previously described. 20 A 533-bp fragment of human OPN cDNA sequence (obtained from ATCC) was used as a probe and labeled with [␥-32 P]dCTP (Amersham Corp) by using a random primer DNA labeling kit (Boehringer Mannheim).
RT-PCR Assays
Total RNA from THP-1 cells was reverse-transcribed by random 9-mers with the use of reverse transcriptase and amplified with Taq DNA polymerase (Takara).
Western Blot Analysis
THP-1 cells were incubated with or without phorbol 12-myristate 13-acetate (PMA) and Tro at a density of 1ϫ10 7 cells/dish for 24 hours. After incubation, proteins from the supernatant were condensed by using Ultra free-PF and PFL filters (Millipore), and then protein extracts were solved with sample buffer (4% SDS, 0.12 mol/L Tris [pH 6.7] , and 20% glycerol). The protein lysis solution was electrophoresed on 15% SDS-polyacrylamide gels and transferred onto nitrocellulose membrane (Schleicher and Schuell, Inc). OPN protein was detected according to the enhanced chemiluminescence protocol (Amersham Corp) using a 1:1000 dilution of a mouse anti-OPN antibody.
Construction of the Luciferase Gene
For generation of luciferase reporter genes, the following forward primers and the reverse primer were used in a PCR reaction with HeLa cell DNA as a template. The forward and reverse primers used for generation of Ϫ1500Luc were 5Ј-CCCGGTACCTCATGAAAG-CTATGAATTAGCTATACA-3Ј and 5Ј-AAACTCGAGGGTCGG-CGTTTGGCTGAGAAGGCTGCA-3Ј with KpnI and XhoI sites (underlined), respectively. The forward and reverse primers used for generation of Ϫ1000Luc were 5Ј-CCCGGTACCAAATGT GCAAAATTTCCTTAT-3Ј and 5Ј-AAACTCGAGGGTCGGC-GTTTGGCTGAGAAGGCTGCA-3Ј; Ϫ970Luc were 5Ј-CCC-GGTACCCAATTTAAAGATCTTACGTCT-3Ј and 5Ј-AAA-CTCGAGGGTC-GGCGTTTGGCTGAGAAGGCTGCA-3Ј. The PCR products were gel-purified, digested, and then subcloned into the KpnI/XhoI sites of pGL3 (Promega).
For generation of mutants, the following forward primers and the reverse primer were used in a PCR reaction with Ϫ1000Luc as a template. The primers (mutations of wild-type sequence appear in bold) for Ϫ1000 mut1Luc, Ϫ1000 mut2Luc, Ϫ1000 mut3Luc, and Ϫ1000 mut4Luc were as follows: Ϫ1000 mut1Luc, 5Ј-CCCGGTACCAAATGTGCAAAGTCCTCTTAT-3Ј; Ϫ1000 mut2Luc, 5Ј-CCCGGTACCAAATGTGCGGAATTTCCTTAT-3Ј; Ϫ1000 mut3Luc, 5Ј-CCCGGTACCAAATGTGCAAGGTTTCCT-TAT-3Ј; and Ϫ1000 mut4Luc, 5Ј-CCCGGTACCAAATGTG-CAAAACCTCCTTAT-3Ј.
4xA/T-TK/luciferase vector (4xA/T-TK/Luc) was prepared as follows: two complementary oligonucleotides containing an A/Trich sequence were annealed and four copies of the annealed oligonucleotides were inserted into TK/Luc, which contains the HSV-1 thymidine kinase (TK) promoter upstream of the luciferase gene. TK/Luc plasmid was a generous gift from Dr Jean-Michel Gauthier (Laboratoire Glaxo Wellcome). The oligonucleotides for 4xA/T-TK/luciferase vector were as follows: top strand, 5Ј-TCGAGAATTTCCTTACCCAATTTCCTTAC-3Ј; bottom strand, 5Ј-TCGAGTAAGGAAATTGGGTAAGGAAATTC-3Ј. 3xPPRE-TK/luciferase vector was kindly provided by Dr S.A. Kliewer (Glaxo Wellcome, London, UK).
Expression Plasmids
Mouse PPAR␥ cDNA was kindly provided by Dr T. Kadowaki (University of Tokyo, Japan). For generation of the coding region of mouse PPAR␥, cDNA was amplified by PCR using the upstream primer with a KpnI site (underlined), 5Ј-GGGGGTACC-ATGGGTGAAACTCTGGGAGAT-3Ј, and the reverse primer with a XbaI site (underlined), 5Ј-CCCTCTAGACTAATACAAGCTCTT-GTAGAT-3Ј. The PCR product was gel-purified, digested, and subcloned into the KpnI/XbaI site of pcDNA3 (Invitrogen).
Transfection and Luciferase Assays
Transfection of THP-1 cells has been performed by the electroporation method as previously reported. 21 Briefly, suspension cultures of 5ϫ10 6 cells were transfected with 3 g of reporter gene along with either 3 g PPAR␥/pcDNA3 or pcDNA3 by setting the capacitance at 975 F and voltage at 250 V. C2/2 cells were transfected with a series of the OPN reporter construct (0.1 g) along with either 1 g of PPAR␥/pcDNA3 or pcDNA3 as previously described. 20 After transfection, cells were exposed to PMA (100 ng/L) alone and in combination with Tro (10 mol/L). THP-1 and C2/2 cells were harvested in cell lysis buffer at 12 and 48 hours after transfection, respectively. Luciferase activities were assayed according to the manufacturer's specifications (Promega).
Electrophoretic Mobility Shift Assays (EMSAs)
Nuclear extracts from THP-1 cells were prepared as previously described. 22 The sequences for the sense strand of double-stranded oligonucleotides used as probes or competitors in EMSAs were as follows, with a consensus motif underlined and mutations of wildtype sequence in bold: OPN (Ϫ995/Ϫ975), 5Ј-TGCAAAATTTCCTTATTGATG-3Ј; mut-1, 5Ј-TGCGGAATT-TCCTTATTGATG-3Ј; mut-2, 5Ј-TGCAAGGTTTCCTTAT-TGATG-3Ј; mut-3, 5Ј-TGCAAAACCTCCTTA-TTGATG-3Ј'; mut-4, 5Ј-TGCAAAATTCTCTTATTGATG-3Ј; mut-5, 5Ј-TGCA-AAATTTCTCTATTGATG-3Ј; mut-6, 5Ј-TGCAAAATT-TCCTCGTTGATG-3Ј; mut-7, 5Ј-TGCAAAATTTCCTTACCG-ATG-3Ј; mut-8, 5Ј-TGCAAAGTCCTCTTATT-GATG-3Ј; PPRE, 5Ј-GACCAGGACAAAGGTCACGTT-3Ј; Ets-1, 5Ј-GTCAGT-TAAGCAGGAAGTGACTAAC-3Ј; homeobox protein, 5Ј-TGCCACTTAATCATTAAGGGAGCC-3Ј; CArG, 5Ј-TCGAG-CCCCAAATATGGAGCCCCAAATATGGAGC-3Ј; and Sp1, 5Ј-ATTCGATCGGGGCGGGGCGAGC-3Ј. Binding reactions were performed as previously described. 23 
Recombinant Adenovirus Expression Constructs
The recombinant adenovirus vectors were generated as previously described. 24 AxCA/LacZ and AxCA/PPAR␥ were prepared by inserting the ␤-galactosidase or PPAR␥2 cDNAs, respectively, into the Ad E1-deleted region under the control the CAG promoter.
Results
Effect of PMA on OPN mRNA Levels
To determine whether OPN mRNA levels are regulated in THP-1 cells, we performed Northern blot analysis and measured OPN mRNA levels after induction of differentiation from monocytes to macrophages with PMA. Whereas the OPN mRNA expression was virtually undetectable in untreated cells, PMA stimulation significantly increased OPN mRNA levels in a time-dependent manner ( Figure 1 ).
Effect of Troglitazone on PMA-Induced OPN Expression
To investigate the effect of PPAR␥ on OPN expression, THP-1 cells were incubated with either PMA alone or in combination with Tro, a PPAR␥ ligand. Northern blot analysis showed that PMA-induced OPN mRNA expression was markedly attenuated in the presence of Tro (Figure 2A ). It should be noted that the decrease in OPN mRNA levels was not due to the nonspecific toxic effect of Tro, because Tro had no inhibitory effects on scavenger receptor-A (SR-A) and PPAR␥ mRNA levels ( Figure 2B ). As shown in Figure 2C , an inhibitory effect of Tro on OPN mRNA expression was dose-dependent: 1 mol/L of Tro has a marked effect on OPN expression, and 10 mol/L of Tro completely inhibited OPN expression. The concentration of Tro used in this study seems to be relevant to the clinical situation because the effective concentration of Tro in the human plasma is Ϸ1.3 mol/L. 25 Western blot analysis confirmed that PMA induces and Tro inhibits the expression of OPN protein. OPN protein levels were detectable after 24 hours of exposure to PMA, and OPN protein was not detected in the presence of Tro ( Figure 2D ).
PPAR␥ Ligands Inhibit OPN Expression
To determine whether the inhibitory effect of Tro on OPN mRNA expression is due to the action of Tro as a PPAR␥ ligand, we next examined the effects of other PPAR␥ ligands on OPN expression. We incubated THP-1 cells with either PMA alone or in combination with Tro, IDM, 15-d-PGJ 2 , or aspirin (Asp) for 24 hours and harvested them for Northern blot analysis. IDM and 15-d-PGJ 2 but not Asp have been described to be ligands of PPAR␥. 11 As shown in Figure 3 , either IDM or 15-d-PGJ 2 completely abolished the induction of OPN mRNA expression by PMA. Consistent with our expectation, Asp had no effect on OPN mRNA expression. These results allowed us to speculate that the inhibitory effect of Tro on OPN expression is mediated through the activation of PPAR␥.
Effect of PPAR␥ on OPN Promoter Activity
To investigate whether PPAR␥ regulates OPN expression at the transcriptional level, we performed transient transfection assays. The luciferase reporter construct containing the OPN promoter region spanning from Ϫ1500 to ϩ87 in front of the luciferase reporter gene, designated as OPN-1500Luc, was transiently transfected into THP-1 cells, and transfected cells were then treated with PMA either in the presence or absence of Tro (Figure 4 ). PMA stimulated luciferase activity of this construct, and more importantly, its activity was significantly repressed by Tro in the presence of PMA. The repression of OPN promoter activity by Tro seems to be dependent on PMA stimulation because Tro had no effect on the OPN promoter in the absence of PMA. We next determined whether PPAR␥ overexpression represses OPN promoter activity. Cotransfection of the PPAR␥ expression plasmid reduced OPN promoter activity either in the absence or presence of PMA. These data are consistent with the hypothesis that Tro inhibits OPN expression at the transcriptional level through the activation of PPAR␥.
To delineate the sequence responsible for the repression of the OPN promoter by PPAR␥, progressive deletion of 5Јflanking region was performed. As shown in Figure 5A , PMA-induced activity was observed in Ϫ1000Luc and Ϫ970Luc, in which the 5Ј ends correspond to Ϫ1000 and Ϫ970, respectively. Luciferase activity of the construct Ϫ1000Luc was reduced by Tro to the same extent as shown in Ϫ1500Luc. In contrast, the decrease in the promoter activity by Tro was not observed in Ϫ970Luc ( Figure 5A ).
We reasoned that if Tro inhibits the luciferase activity of Ϫ1500Luc and Ϫ1000Luc, but not Ϫ970Luc, through PPAR␥ activation, then overexpression of PPAR␥ could exert the same affects on the OPN promoter as those seen by Tro stimulation. As shown in Figure 5B , overexpression of PPAR␥ decreased the luciferase activity of Ϫ1500Luc and Ϫ1000Luc but not Ϫ970Luc in THP-1 cells.
To further assess the role of PPAR␥ in the repression of OPN promoter activity, we used the C2/2 cells, smooth muscle cells derived from rabbit aorta, as the possible PPAR␥-deficient cells. Figure 5C reveals that in the absence of PPAR␥ expression vector Tro has only minimally increased luciferase activity of 3xPPRE/Luc, which contains three copies of rat acly-CoA oxidase PPRE in front of the TK basal promoter. The ability of 3xPPRE/Luc to respond to Tro was verified by showing that Tro enhanced the PPAR␥induced activity of 3xPPRE/Luc activity. These data suggest that C2/2 cells express little, if any, functional PPAR␥. As shown in Figure 5D , PPAR␥ overexpression strongly reduced the promoter activity of Ϫ1500Luc and Ϫ1000Luc but not Ϫ970Luc in C2/2 cells. These results indicate that PPAR␥ reduces OPN promoter activity in C2/2 and THP-1 cells and suggest that the sequence between Ϫ1000 and Ϫ970 contains a regulatory element responsible for PPAR␥-induced repression of OPN promoter activity regardless of the cell types.
Identification of Nuclear Factor-Binding Sites Between ؊1000 and ؊970
To determine whether the sequence between Ϫ1000 and Ϫ970 of the OPN promoter interacts with the nuclear proteins, we performed EMSAs by using double-stranded oligonucleotides containing the sequence from Ϫ995 to Ϫ975 as a probe. Results showed that incubation of nuclear extracts prepared from PMA-stimulated THP-1 cells gave rise to two prominent shifted complexes, C1 and NS. To determine the sequence specificity of these complexes, we Figure 5 . Mapping of cis-regulatory elements involved in a downregulation of OPN promoter by PPAR␥. A, Series of 5Ј-deletion reporter constructs containing the OPN promoter region and the luciferase gene were transfected into THP-1 cells. Transfection into THP-1 cells was performed by the electroporation method. After transfection, THP-1 cells were stimulated with PMA (100 ng/mL) and Tro (10 mol/L). After 12 hours of posttransfection, cells were harvested and luciferase activities were measured. Luciferase activities are expressed relative to that of pGL3, which is set at 1.0. Values are meanϮSEM for 3 separate experiments. B, THP-1 cells were transfected with a series of 5Ј-deletion constructs of OPN promoter reporter plasmids along with pcDNA3 (empty vector) or PPAR␥/pcDNA3 (PPAR␥-expressing vector). After transfection, cells were stimulated with PMA (100 ng/mL). Luciferase activities are expressed relative to that of pGL3, which is set at 1.0. Values are meanϮSEM for 3 separate experiments. C, C2/2 cells were transfected with 3xPPRE-TK/Luc along with either pcDNA3 or PPAR␥/pcDNA3. Transfected cells were either stimulated with vehicle or Tro (10 mol/L) for 12 hours. Luciferase activities are expressed relative to that of TK/Luc, which is set at 1.0. Values are meanϮSEM for 3 separate experiments. D, C2/2 cells were transfected with a series of 5Ј-deletion constructs of OPN promoter reporter plasmids along with pcDNA3 (empty vector) or PPAR␥/pcDNA3 (PPAR␥-expressing vector). Luciferase activities are expressed relative to that of pGL3, which is set at 1.0. Values are meanϮSEM for 3 separate experiments. performed the competitive EMSAs by using the unlabeled oligonucleotides containing two successive mutations within the probe sequence as competitors. As shown in Figure 6 , addition of 100-fold molar excess of unlabeled probe sequence completely abolished the complex C1 but not NS, suggesting that complex NS seems to be nonspecific. Formation of complex C1 was abolished by mut-1 and mut-7, but not by mut-2, mut-3, mut-4, mut-5, and mut-6. Based on the sequence mutated in mut-2, mut-3, mut-4, mut-5, and mut-6, these results indicate that the sequence involved in the complex C1 formation is localized to the position between Ϫ990 and Ϫ981, 5Ј-AATTTCCTTA-3Ј.
We next tested whether PPAR␥ affects the amount of complex C1. As shown in Figure 7A , the intensity of complex C1 was modestly but reproducibly increased in the nuclear extracts prepared from the cells treated with PMA. It is noticeable that the intensity of PMA-induced complex was decreased by Tro. The intensity of Sp1 binding was equivalent among samples used in the EMSAs, indicating that an observed change in intensity of C1 complex is not due to the difference or variation in quality and quantity of the nuclear extracts used. Furthermore, forced expression of PPAR␥ by AxCA/PPAR␥ decreased the intensity of C1 complex compared with the LacZ overexpression ( Figure 7B ). Next, to investigate whether C1 complex contains PPAR␥, we performed a supershifted assay. As shown in Figure 7C , anti-PPAR␥ antibody had no effect on complex C1 formation. The integrity of anti-PPAR␥ antibody was confirmed by incubating the nuclear extract prepared from AxCA/PPAR␥-infected cells with the probe containing PPRE, a PPAR-responsive element. Expectedly, the PPRE probe gave rise to a DNA:protein complex, and anti-PPAR␥ antibody supershifted this complex (Figures 7A and 7B) . These results suggest that PPAR␥ does not bind to the sequence OPN (Ϫ995/Ϫ975).
To better characterize the nuclear proteins participating in the complex formation, we tested whether some of the sequences known as targets of DNA binding proteins can compete for the binding to the probe. Searching for the DNA binding proteins whose recognition sequence resembles the probe sequence reveals that the sequence 5Ј-AATTTCCTTA-3Ј is similar to the DNA binding sequence for homeobox proteins, whose consensus binding sequence is 5Ј-CAATTAA-3Ј. As shown in Figure 7D , the addition of the unlabeled oligonucleotide containing the consensus sequence for the homeobox protein but not for CArG, Sp1, and Ets-1 has measurable effects on complex formation. These data suggest that the A/T-rich sequence between Ϫ990 and Ϫ981, which may be recognized by homeobox proteins or related proteins but not by PPAR␥, is important for the inhibitory effects of PPAR␥ on OPN gene expression.
Effect of Mutation of A/T-Rich Sequence on the OPN Promoter Activity
The role of the A/T-rich sequence in the inhibitory effects of PPAR␥ on OPN gene expression prompted us to explore the possibility that mutation of this sequence may abolish the effects of Tro on OPN promoter activity. We made constructs in which the mutation was introduced into this 10-bp sequence in the context of Ϫ1000Luc ( Figure 8A ). The constructs Ϫ1000 mut2Luc and Ϫ1000 mut3Luc, both containing a mutation within the 10 base pairs, failed to respond to the overexpression of PPAR␥. The construct Ϫ1000 mut1Luc, which contains a mutation outside the 10 base pairs, exhibited the same reduction in luciferase activity in response to PPAR␥ overexpression.
To further verify that PPAR␥ represses OPN promoter activity through the A/T-rich sequence, we made a construct, 4xA/T-TK/Luc, in which 4 copies of fragments containing 5Ј-AATTTCCTTA-3Ј were inserted into HSV-1 TKluciferase promoter vector TK/Luc. As shown in Figure 8B , the promoter activity of the 4xA/T-TK/Luc was reduced by the PPAR␥ expression vector. From these results, we conclude that the 10-bp sequence 5Ј-AATTTCCTTA-3Ј mediates the inhibitory effects of PPAR␥ on OPN promoter activity. It is also of interest to note that luciferase activity of 4xA/T-TK/Luc is lower than that of TK/Luc, suggesting that the A/T-rich sequence when multimerized may act as a negative element.
Discussion
Increasing evidence indicates an important role of PPAR␥ activation in modulating the development and progression of atherosclerosis. Several reports have demonstrated that PPAR␥ ligands inhibit growth factor-mediated growth and Figure 6 . Identification of nuclear factor-binding sites between Ϫ1000 and Ϫ970. A, Top, Nucleotide sequences of the oligonucleotides used in the competitive EMSA are shown. Probe sequence is derived from the OPN promoter spanning between Ϫ995 and 975. Two successive mutations introduced into this sequence are indicated by bold letters. Sequence between Ϫ990 and Ϫ981, 5Ј-AATTTCCTTA-3Ј, which serves as a nuclear factor-binding site (see below), is boxed. Bottom, EMSA. Nuclear extracts (10 g) prepared from unstimulated THP-1 cells were incubated with 32 P-labeled Ϫ995/Ϫ975 probe, in the absence or presence of a 100-fold molar excess of indicated unlabeled competitors. Positions of the sequence-specific DNA:protein complex C1 and nonspecific binding (NS) are indicated.
migration of vascular smooth muscle cells. 26, 27 Furthermore, PPAR␥ ligands exert their role as negative regulators of macrophage activation and inflammatory cytokine production. 16, 17 We have recently found that the expression of the OPN gene is induced upon stimulation by PMA and that PPAR␥ ligands reduce PMA-induced OPN gene expression. 18 In the present study, we explored the molecular mechanisms behind this observation. We demonstrated that OPN gene expression can be regulated at the transcriptional level in monocytic leukemia cells, THP-1 cells. In addition, we demonstrated that the A/T-rich sequence on the OPN promoter lying between Ϫ990 and Ϫ981 serves as an essential motif for the repression of the transcription by PPAR␥. Results of the EMSA suggest that PPAR␥ inhibits the binding of the nuclear factor to the OPN promoter.
Our findings that PPAR␥ ligands inhibit the expression of the OPN gene will carry considerable clinical significance from the viewpoint of the effectiveness of PPAR␥ agonists as antiatherosclerotic drugs. Such an effect of PPAR␥ ligands on OPN expression suggests the beneficial role of PPAR␥ activators because OPN has recently been implicated in neointimal formation, atherosclerogenic progression, and vascular calcification. [5] [6] [7] This assumption is supported by previous reports indicating that PPAR␥ activators prevented the induction of inflammatory cytokine production and matrix metalloproteinase production from stimulated monocytes/macrophages. 28 Furthermore, PPAR␥ activators have been suggested to inhibit the initiation of atherosclerosis by inhibiting the expression of VCAM-1 in endothelial cells. 29 Figure 7 . EMSA. A, Nuclear extracts (10 g) prepared from either unstimulated, PMA-treated, PMAϩTro-treated, or Trotreated THP-1 cells were incubated with 32 P-labeled Ϫ995/Ϫ975 probe. Position of the sequence-specific DNA:protein complex (C1) is indicated. Same experiments were performed using the Sp1 consensus sequence as a probe. B, COS-7 cells were infected with AxCA/ LacZ or AxCA/PPAR␥. Nuclear extracts prepared from COS-7 cells were incubated with Ϫ995/Ϫ975 probe or PPRE probe. Sequence for PPRE probe is shown in Materials and Methods. DNA:protein complex containing PPAR␥ is indicated. NS indicates nonspecific complex. C, Supershift assays using nuclear extracts prepared from PMAtreated THP-1 cells were performed using indicated antibodies. Supershifted complex (SS) is indicated by arrow. D, Competition assays. Nuclear extracts (10 g) prepared from either PMA-stimulated THP-1 cells were incubated with 32 Plabeled Ϫ995/Ϫ975 probe, in the absence or presence of a 100-fold molar excess of indicated unlabeled competitors. Sequence of the unlabeled competitor mut-8, which contains mutation within the sequence Ϫ990/Ϫ981 is indicated by bold letters. Consensus binding sequences for homeobox binding proteins (Homeo), CArG, Sp1, and Ets-1 are shown in Materials and Methods. Position of the sequence-specific DNA:protein complex (C1) is indicated. All these observations favor the hypothesis that PPAR␥ ligands act as antiatherosclerotic medicines.
It is worth stressing that under our experimental conditions, we found that Tro inhibits the apolipoprotein E (apoE) mRNA expression, which is highly induced in the absence of Tro. We also noted that induced expression of SR-A and lipoprotein lipase (LPL) during differentiation from monocytes to macrophages was augmented by Tro (data not shown). Considering the fact that apoE is essential for LDL receptors to recognize LDL particles, the reduction of apoE by Tro seems to be unfavorable to atherosclerotic lesions. Similarly, an increase in LPL and SR-A expression by Tro may aggravate the lesions. Taken together with the previous report by Tontonoz et al, 15 who showed that PPAR␥ activators promote monocytic differentiation, we need to be aware that activation of PPAR␥ may have unfavorable effects on preexisting vascular lesions. Recent studies, however, showed that PPAR␥ activators do not enhance the ox-LDL uptake of macrophages, although CD36 gene expression from macrophages is increased by PPAR␥ activators. 17, 30 More recent work demonstrated that Tro inhibits the fatty streak lesion formation in apoE-knockout mice. 31 These results suggest that despite the pleiotropic effects of Tro on the gene expression in the vascular wall, it acts as an antiatherosclerotic rather than proatherosclerotic medicine.
The specificity of an inhibition of OPN gene expression by Tro should be stressed because Tro contains a vitamin E moiety that endows it with some antioxidant properties. 32 Our findings show that both 15d-PGJ 2 and IDM, which act as PPAR␥ ligands, inhibited OPN expression to a similar extent as Tro. The inability of Asp, which is not considered to be a PPAR␥ activator, to inhibit OPN expression supports our findings that inhibition of OPN expression is not due to the nonspecific effects of antiinflammatory agents.
Although PPAR␥ is known to change gene transcription through its responsive element, PPRE, 33 several reports have indicated that PPARs regulate gene expression independent of PPRE. Tolon et al 34 have reported that PPAR␥ inhibits prolactin gene activation by inhibiting the function of GHP-1, a transcription factor implicated in pituitary-specific gene expression. Ricote et al 16 postulated that PPAR␥ ligands inhibit the expression of the inducible form of NO synthase, gelatinase B, and SR-A expression by interfering with the function of AP-1, STAT-1, and NF-B. In the present study, we defined the A/T-rich sequence located at Ϫ990 as a regulatory element of PPAR␥. We partially characterized the factors, which recognize the A/T-rich sequence by competitive EMSA, and showed that homeobox proteins or related factors may constitute the complex formation with this element. Identification of DNA-binding protein on A/T-rich sequence will merit further studies.
In conclusion, the present study showed that OPN production was significantly reduced in response to the ligand-activated PPAR␥. Although our studies do not address the question whether PPAR␥ activators serve as antiatherosclerotic medicine in vivo, our findings may provide new insight into the molecular mechanisms by which activators of PPAR␥ modify vascular lesions because OPN expression is intimately associated with the development of atherosclerosis.
